Grantham, Mayo, Van Otterloo & Co (GMO)’s Vanda Pharmaceuticals VNDA Stock Holding History
Bought
Maintained
Sold
Other funds holding VNDA
ACM
Grantham, Mayo, Van Otterloo & Co (GMO)'s VNDA Position: Q3 2026 in Review
Grantham, Mayo, Van Otterloo & Co (GMO) reduced its Vanda Pharmaceuticals (VNDA) stake by 23% in Q3 2026, selling an estimated $35.5K and leaving 21,737 shares worth $107K. The position accounts for ﹤0.01% of the portfolio, ranked #675.
Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in VNDA in Q1 2020 and has held it in 8 quarters since. The position peaked at $1.91M in Q2 2020. 152 funds tracked by Wall St. Rank hold VNDA as of Q3 2026.
- Grantham, Mayo, Van Otterloo & Co (GMO) held 21,737 shares of Vanda Pharmaceuticals worth $107K as of Q3 2026.
- Grantham, Mayo, Van Otterloo & Co (GMO) sold 6,607 Vanda Pharmaceuticals shares in Q3 2026, an estimated $35.5K.
- Vanda Pharmaceuticals made up ﹤0.01% of Grantham, Mayo, Van Otterloo & Co (GMO)'s portfolio in Q3 2026, its #675 holding.
- Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in Vanda Pharmaceuticals in Q1 2020 and has held it in 8 quarters since.
- Grantham, Mayo, Van Otterloo & Co (GMO)'s Vanda Pharmaceuticals position peaked at $1.91M in Q2 2020.
- 152 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2026.
Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q3 2026, filed 13 Nov 2026.